Study on Factors Affecting How Well Ruxolitinib Cream Works to Treat Vitiligo in Patients Aged 12 and Older

What this Trial Is About

Vitiligo is a common chronic autoimmune skin condition causing white patches on the skin that can affect any area of the body and significantly reduce quality of life. Current treatments like topical medications, phototherapy, systemic therapy, and surgery often have limited success and high rates of recurrence. This research focuses on studying ruxolitinib cream, a JAK inhibitor, to understand what factors influence its effectiveness in treating vitiligo in a real-world setting. Participants in this observational study will use ruxolitinib cream twice daily. The study aims to assess the creams impact on vitiligo by measuring improvements in skin depigmentation using tools like the total vitiligo area scoring index T-VASI and the facial vitiligo area scoring index F-VASI over 24 weeks. Secondary assessments include patient-reported noticeability of vitiligo patches and quality of life changes. During the study, participants will be monitored at weeks 12 and 24 for changes in vitiligo severity and quality of life. Researchers will evaluate clinical differences between those achieving significant improvement and those who do not. Participants must agree to stop other vitiligo treatments during the study and use effective contraception if applicable. The total participation duration extends over 24 weeks with scheduled assessments to track treatment response and safety.

A Real-world Study on the Influencing Factors of Efficacy of Ruxolitinib Cream in Vitiligo